Table 1—

Quality of life as reported by type 2 diabetic patients

EQ5D utility score (n=1136)Euroqol VAS score (n=1,224)
Overall0.74 (0.27)0.68 (0.18)
Sex
    Female0.70 (0.28)0.67 (0.18)
    Male0.79 (0.25)0.70 (0.18)
Age
    <50 years0.79 (0.26)0.69 (0.19)
    50–59 years0.75 (0.26)0.69 (0.18)
    60–69 years0.78 (0.25)0.70 (0.18)
    ≥70 years0.70 (0.28)0.67 (0.18)
Duration of diabetes
    <5 years0.77 (0.25)0.70 (0.17)
    5–10 years0.73 (0.29)0.67 (0.19)
    ≥10 years0.70 (0.29)0.66 (0.18)
Treatment
    Diet and exercise only0.79 (0.26)0.73 (0.17)
    Oral therapy only0.76 (0.25)0.69 (0.17)
    Insulin only or combined0.63 (0.30)0.61 (0.20)
Complications
    No complications0.81 (0.23)0.72 (0.16)
    Only microvascular complications0.72 (0.28)0.67 (0.18)
    Only macrovascular complications0.73 (0.27)0.66 (0.17)
    Microvascular and macrovascular complications0.61 (0.31)0.62 (0.20)
Obesity0.70 (0.28)0.66 (0.19)
No obesity0.77 (0.26)0.69 (0.17)
  • Data are means (SD). Note: microvascular complications were defined as foot ulcer, blindness, photocoagulation or vitrectomy, dialysis, renal transplant, retinopathy, neuropathy, manifest nephropathy, and microalbuminuria. Macrovascular complications were defined as myocardial infarction, angina, heart failure, cardiac surgery (coronary artery bypass grafting, percutaneous transluminal angioplasty), stroke, transient ischemic attack, and peripheral vascular disease.